Thalidomide for inflammatory bowel disease: Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 2, 2002, Pages 135-139

  Bariol, Carolyn ^a,b   Meagher, Alan P ^a   Vickers, Christopher R ^a   Byrnes, David J ^a   Edwards, Paul D ^a   Hing, Michael ^a   Wettstein, Antony R ^a   Field, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Crohn's disease; Thalidomide; Tumor necrosis factor ; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; SUARAMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ANUS CONTINENCE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; COLONOSCOPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTOPATHOLOGY; HUMAN; MALE; NERVE CONDUCTION; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; XEROSTOMIA; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; COLITIS; COLITIS, ULCERATIVE; COLONOSCOPY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; THALIDOMIDE;

EID: 0036481989     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02564.x     Document Type: Article

References (25)

1. Use of thalidomide in leprosy
2. Thalidomide for the treatment of chronic GVHD
3. Thalidomide: Treatment of severe recurrent aphthous stomatitis in patients with AIDS
4. Thalidomide and cell-mediated immunity in Behcet's disease
5. Thalidomide selectively inhibits tumour necrosis factor alpha reduction by stimulated human monocytes
6. TNFα-producing cells in the intestinal mucosa of children with IBD
7. TNFα in stool as a marker of intestinal inflammation
8. Enhanced secretion of TNFα IL6, IL1-B by isolated lamina propria cells from patients with ulcerative colitis and Crohn's disease
9. Inflammatory properties of recombinant tumour necrosis factor in rabbit skin in vivo
10. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (cA2)
11. Thalidomide in Crohn's disease
12. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease study
13. Location and activity of ulcerative colitis and Crohn's disease by Indium 111 Leucocyte Scan. A prospective comparison study
14. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study
15. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
16. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
17. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production
18. Development of polyneuropathy during thalidomide therapy
19. Thalidomide neuropathy: A clinical, electrophysiological and histological follow up study
20. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis
21. Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection
22. Thalidomide as treatment of oral aphthous ulceration in patients with HIV infection
23. Phase II evaluation of thalidomide in patients with metastatic breast cancer
24. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
25. Anti-tumour necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety